Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 89
- Registration Number
- NCT01467375
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Saskatoon, Canada
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Drug: biphasic human insulin
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 303
- Registration Number
- NCT01467323
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Whiston, United Kingdom
Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 182
- Registration Number
- NCT01465152
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01464099
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01455142
Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice
Completed
- Conditions
- Delivery SystemsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes
- Interventions
- Device: FlexPen®Device: NovoPen® 3
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1031
- Registration Number
- NCT01454024
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01448070
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01437592
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Changing Diabetes® World Tour
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 8304
- Registration Number
- NCT01437072
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Dubai, United Arab Emirates
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 349
- Registration Number
- NCT01435642
- Locations
- 🇩🇿
Novo Nordisk Investigational Site, Blida, Algeria
© Copyright 2025. All Rights Reserved by MedPath